Variation and location of cytochrome P450 isoenzyme expression in various organs of male F344 rats treated with 1, 2-dimethylhydrazine (DMH), N, N-dibutylnitrosamine (DBN), and methylbenzylnitrosamine (MBNA) were immunohisto chemically and biochemically investigated. The animals received MBNA (6mg/6ml/kg b. w. i. p.) in corn oil, DBN (400mg/ 4ml/kg b. w. i. p.) in distilled water with Tween 80, or DMH (40mg/4ml/kg b. w. i. p.) dissolved in saline. All animals were sacrificed at hours 15 after administration of the test compound.
Introduction
The mammalian cytochrome P450 isoenzymes play an important role in toxcity and carcinogenesis of chemicals, since most members can activate a wide range of chemicals into highly reactive toxic and carcinogenic substances2. Recently, several cytochrome P450 isoenzymes have been purified and characterized from various organs and tissues in experimental animals and man 3-1. The activities of carcino gens and their metabolites depend to the composition of these cytochrome P450 isoenzymes.
Although the liver is general ly the organ with the highest content of the isoenzymes, some researchers reported that they are also present in other tissues, including the small intestine, colon, kidney, lung, and skin6-8. These tissues thus have sufficient activity to generate toxic metabolites of certain administered chemicals. The avidin-biotin-peroxidase complex (ABC) method described by Hsu et al.13 was used to demonstrate cyto chrome P450 immunohistostaining.
After deparaffinization, tissue sections were sequentially treated with normal goat serum, anti-rabbit cytochrome P450 antibody (1:1,000), biotin-labeled goat anti-rabbit IgG (1:400), and ABC. The sites of peroxidase binding were demonstrated by the diaminobenzidine method.
Sections were then counter stained with hematoxylin for microscopic examination.
The polyclonal antibodies against CYP1A1, 2C11, 2D1, 2E1, 3A2, and 4A1 utilized in this study were raised as described earlier14. Anti-CYP1A1 antibody was found to cross-react ed with CYP1A2 as well as with CYP1A, but these forms were separable by SDS-polyacrylamide gel electrophoresis. Anti-CYP2C11 antibody mainly reacted with CYP2C11 and weakly cross-reacted with CYP2C13 and CYP2C6. Anti CYP2D1 antibody weakly cross-reacted with the CYP2D family only. CYP2C11 expression in the centrilobular areas of the liver in rats treated with DBN or DMH was immunohisto chemically weaker than in the untreated control liver case (Fig. 1 ). There were no immunohistochemical differences for CYP2C11 protein expression in other organs such as the lung, esophagus, stomach, small intestine, large intestine, kidney, seminal vesicles, prestate, and urinary bladder. MBNA did not change CYP2C11 protein expression in all organs examined including the liver. CYP2D1 expression was immunohistochemically observed in periportal areas of the liver in rats treated with MBNA (Fig. 2) , but not in the untreated control liver case. There was no difference for CYP2D1 expression in other Results of Western blotting analysis of cytoplasmic preparations from the livers of rats treated with DBN or DMH are shown in Fig. 3 . The levels of CYP2C11 protein in the liver are shown in Fig. 4 , values being significantly decreased in rats treated with DBN.
A trend for CYP2C11
protein decrease was noted in animals treated with DMH.
Discussion
The present study of levels and localization of CYP2C11 and CYP2D1 in the liver of rats treated with MBNA, DBN, or DMH provided immunohistological and biochemical evidence of variation. Also human exposure to MBNA has been associated with an increased incidence of esophageal carcinomas in China22-24. Any relation between the esophageal carcinogenic effect of MBNA and CYP2D1 induction in the liver needs to be established.
The physiological basis for 3-MC amplification of the expression of cytochrome P450 isoenzymes not only in the liver but also in other organs remains to be determined in our last study12.
In conclusion, the present investigation demonstrated that expression of cytochrome P450 isoenzymes can modulate exogenous agents in the liver. 
